Summary

PEG-MGF (PEGylated Mechano Growth Factor) is a chemically modified form of MGF, a splice variant of insulin-like growth factor 1 (IGF-1) that is naturally produced in skeletal muscle in response to mechanical overload. The PEGylation extends its half-life significantly compared to unmodified MGF. Research in animal and cell models suggests MGF may promote muscle satellite cell activation and local tissue repair, though human clinical data remains extremely limited. PEG-MGF is not a licensed medicine in the UK and exists in a regulatory grey area as a research chemical.

Mechanism

MGF (Mechano Growth Factor) is a splice variant of the IGF-1 gene, produced locally in skeletal muscle in response to mechanical overload or damage. Unlike systemic IGF-1 (IGF-1Ea), MGF contains a unique C-terminal E-domain sequence that appears to activate muscle satellite cells (muscle stem cells) rather than acting through the IGF-1 receptor alone. The PEGylation process attaches polyethylene glycol chains to the peptide, which extends half-life by reducing renal clearance and proteolytic degradation. The extended half-life is the primary pharmacological rationale for PEG-MGF over native MGF, though specific pharmacokinetic data for the PEGylated form has not been published in peer-reviewed literature.

Evidence base

Evidence for PEG-MGF is limited. Most research concerns native MGF or MGF E-domain peptides, not the PEGylated form specifically. Foundational work by Yang et al. (1996, EMBO Journal) identified MGF as an IGF-1 splice variant produced after muscle overload [1]. Mills et al. (2007, J Physiology) demonstrated satellite cell activation by MGF E-domain in vitro [2]. Dluzniewska et al. (2006) suggested neuroprotective potential in a rat ischaemia model [3]. Owino et al. (2001, Mechanisms of Ageing and Development) showed age-related decline in MGF expression [4]. No published human clinical trials exist for PEG-MGF. All findings should be considered preliminary, based on animal or in vitro models.

Protocols

In research contexts, PEG-MGF is commonly discussed as subcutaneous or intramuscular injection at 200–400 micrograms, 1–3 times weekly, for 4–6 week cycles. Some researchers favour post-exercise administration. No human dosing studies have been published. These are research-community discussions, not medical dosing instructions.

PEG-MGF is not a licensed UK medicine and is not a controlled substance. It exists in a regulatory grey area: purchasable for research purposes but not MHRA-approved for human therapeutic use. Selling for human consumption would violate UK medicines legislation.

Vendor notes

Vendor listings will appear here as UK vendors are independently verified by Peptide Data.

References

  1. Yang SY, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterisation of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. The EMBO Journal. 1996;15(13):2945-2952.
  2. Mills P, Dominique FE, Bhatt B, Jiang J, Ridgway K, Schiff MA, et al. Effect of mechano-growth factor on satellite cell activation and muscle regeneration in vitro. The Journal of Physiology. 2007;583(Pt 1):333-342.
  3. Dluzniewska J, Sarnowska A, Beresewicz M, Johnson I, Srai SK, Ramesh B, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB Journal. 2006;20(13):2406-2417.
  4. Owino V, Yang SY, Goldspink G. Age-related loss of skeletal muscle function and the inability to express MGF in response to mechanical overload. Mechanisms of Ageing and Development. 2001;122(9):953-963.